title: Pharmacogenetics of second-generation antipsychotics.
abstract: This review considers pharmacogenetics of the so called 'second-generation' antipsychotics. Findings for polymorphisms replicating in more than one study are emphasized and compared and contrasted with larger-scale candidate gene studies and genome-wide association study analyses. Variants in three types of genes are discussed: pharmacokinetic genes associated with drug metabolism and disposition, pharmacodynamic genes encoding drug targets, and pharmacotypic genes impacting disease presentation and subtype. Among pharmacokinetic markers, CYP2D6 metabolizer phenotype has clear clinical significance, as it impacts dosing considerations for aripiprazole, iloperidone and risperidone, and variants of the ABCB1 gene hold promise as biomarkers for dosing for olanzapine and clozapine. Among pharmacodynamic variants, the TaqIA1 allele of the DRD2 gene, the DRD3 (Ser9Gly) polymorphism, and the HTR2C -759C/T polymorphism have emerged as potential biomarkers for response and/or side effects. However, large-scale candidate gene studies and genome-wide association studies indicate that pharmacotypic genes may ultimately prove to be the richest source of biomarkers for response and side effect profiles for second-generation antipsychotics.
authors.affiliation: Department of Biochemistry & Molecular Biology, School of Medicine, University of Louisville, Louisville, KY 40292, USA. mark.brennan@suregene.net.
authors.forename: Mark D
authors.initials: MD
authors.lastname: Brennan
mesh_terms: D000483:Alleles; D014150:Antipsychotic Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000378:metabolism; D064420:Drug-Related Side Effects and Adverse Reactions / Q000235:genetics; D055106:Genome-Wide Association Study / Q000379:methods; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*; D011110:Polymorphism, Genetic / Q000235:genetics
chemical_list: D014150:Antipsychotic Agents; D015415:Biomarkers
keywords: atypical antipsychotics; biomarkers; pharmacodynamics; pharmacogenomics; pharmacokinetic; pharmacotypic; response; side effects